On March 28, 2023,
Benchmark
initiated coverage of Repligen with
a Buy recommendation.
Analyst Price Forecast Suggests 23.54% Upside
As of March 29, 2023,
the average one-year price target for Repligen is $207.26.
The forecasts range from a low of $97.97 to a high of $262.50.
The average price target represents an increase of 23.54% from its latest reported closing price of $167.77.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Repligen
is $825MM, an increase of 2.90%.
The projected annual non-GAAP EPS
is $3.05.
What are Large Shareholders Doing?
Price T Rowe Associates
holds 5,071K shares
representing 9.11% ownership of the company.
In it’s prior filing, the firm reported owning 3,660K shares, representing
an increase
of 27.83%.
The firm
increased
its portfolio allocation in RGEN by 23.11% over the last quarter.
PRNHX – T. Rowe Price New Horizons Fund
holds 3,554K shares
representing 6.39% ownership of the company.
In it’s prior filing, the firm reported owning 2,390K shares, representing
an increase
of 32.77%.
The firm
increased
its portfolio allocation in RGEN by 37.86% over the last quarter.
Sands Capital Management
holds 1,781K shares
representing 3.20% ownership of the company.
In it’s prior filing, the firm reported owning 1,639K shares, representing
an increase
of 8.00%.
The firm
decreased
its portfolio allocation in RGEN by 0.99% over the last quarter.
VTSMX – Vanguard Total Stock Market Index Fund Investor Shares
holds 1,688K shares
representing 3.03% ownership of the company.
In it’s prior filing, the firm reported owning 1,652K shares, representing
an increase
of 2.13%.
The firm
decreased
its portfolio allocation in RGEN by 14.62% over the last quarter.
Wcm Investment Management
holds 1,602K shares
representing 2.88% ownership of the company.
In it’s prior filing, the firm reported owning 1,520K shares, representing
an increase
of 5.14%.
The firm
decreased
its portfolio allocation in RGEN by 13.17% over the last quarter.
What is the Fund Sentiment?
There are 1019 funds or institutions reporting positions in Repligen.
This is an increase
of
45
owner(s) or 4.62% in the last quarter.
Average portfolio weight of all funds dedicated to RGEN is 0.38%,
a decrease
of 9.00%.
Total shares owned by institutions increased
in the last three months by 4.54% to 67,749K shares.
The put/call ratio of RGEN is 0.57, indicating a
bullish
outlook.
Repligen Background Information
(This description is provided by the company.)
Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that increase efficiencies in the process of manufacturing biological drugs. Its primary customers are biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Its corporate headquarters are located in Waltham, Massachusetts, with additional administrative and manufacturing operations worldwide. The majority of its manufacturing sites are located within the U.S. (California, Massachusetts, New Jersey and New York), and outside of the U.S. it has sites in Estonia, Germany, Ireland, the Netherlands and Sweden.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
